Presentation is loading. Please wait.

Presentation is loading. Please wait.

Shannon Otsuka, BSc, Gwyn Bebb, BMBCh, PhD, FRCPC 

Published byThomasina Harrell Modified over 5 years ago

Similar presentations

Presentation on theme: "Shannon Otsuka, BSc, Gwyn Bebb, BMBCh, PhD, FRCPC "— Presentation transcript:

1 The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target Therapeutic for Non-small Cell Lung Cancer 
Shannon Otsuka, BSc, Gwyn Bebb, BMBCh, PhD, FRCPC  Journal of Thoracic Oncology  Volume 3, Issue 12, Pages (December 2008) DOI: /JTO.0b013e31818dda9d Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Schematic illustrating molecular pathways by which CXCR4 acts. Stromal cell derived factor (SDF-1) bound-CXCR4, possibly after incorporation into lipid rafts, acts via Gαi, to activate the phosphoinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signaling pathways. Activated CXCR4 increases intracellular calcium mobilization and induces phosphorylation of focal adhesion components such as FAK and Pyk2. The activated signal transduction pathways contribute to chemotaxis, cell migration, and secretion of various matrix metalloproteinases (MMP's) including MMP-2 and MMP-9. Supporting references in brackets. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31818dda9d) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Shannon Otsuka, BSc, Gwyn Bebb, BMBCh, PhD, FRCPC "

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Volume 7, Issue 3, Pages (March 2005)

Volume 7, Issue 3, Pages (March 2005)
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Urokinase-induced smooth muscle cell responses require distinct signaling pathways: A role for the epidermal growth factor receptor  Suzanne M. Nicholl,

Urokinase-induced smooth muscle cell responses require distinct signaling pathways: A role for the epidermal growth factor receptor  Suzanne M. Nicholl,
Signaling molecules as therapeutic targets in allergic diseases

Signaling molecules as therapeutic targets in allergic diseases
Tumor necrosis factor: Biology and therapeutic inhibitors

Tumor necrosis factor: Biology and therapeutic inhibitors
Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Personalizing Therapy for Colorectal Cancer

Personalizing Therapy for Colorectal Cancer
Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung.

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung.
Axl Receptor Axis: A New Therapeutic Target in Lung Cancer

Axl Receptor Axis: A New Therapeutic Target in Lung Cancer
Rebecca Muirhead, MBChB, MRCP, Stuart G

Rebecca Muirhead, MBChB, MRCP, Stuart G
Chadrick E. Denlinger, MD, John S. Ikonomidis, MD, PhD, Carolyn E

Chadrick E. Denlinger, MD, John S. Ikonomidis, MD, PhD, Carolyn E
Personalizing Therapy for Colorectal Cancer

Personalizing Therapy for Colorectal Cancer
A Radical Role for p38 MAPK in Tumor Initiation

A Radical Role for p38 MAPK in Tumor Initiation
OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

Similar presentations

Ads by Google